10 Jan
2022
16:30 E.S.T.

Cellectis’ Licensed Partner, Allogene Therapeutics,  Announces Removal of FDA Clinical Hold on their Clinical Trials

Read more

04 Jan
2022
14:37 E.S.T.

Cellectis Provides Business Objectives for 2022 and Updates its Corporate Presentation

Read more

11 Dec
2021
10:11 E.S.T.

Cellectis Reports Encouraging Clinical Data from BALLI-01 Study in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, and Preclinical Data from TALGlobin01 at the 63rd American Society of Hematology Annual Meeting

Read more

18 Nov
2021
13:44 E.S.T.

Cytovia and Cellectis Expand Their TALEN® Gene-Edited iNK Partnership to Enable Broader Collaboration in China

Read more

11 Nov
2021
17:19 E.S.T.

Cellectis Presents First Preclinical Data on UCARTMESO, an Allogeneic CAR-T Cell Product Candidate Targeting Mesothelin to Treat Solid Tumors at the Annual Meeting of the Society for Immunotherapy of Cancer

Read more

04 Nov
2021
14:51 E.S.T.

Cellectis Provides Business Update and Reports Financial Results for Third Quarter and First Nine Months 2021

Read more

03 Nov
2021
18:40 E.S.T.

Cellectis Announces Release of Abstracts at ASH Showcasing Updated Preliminary Clinical Data from BALLI-01 Study and First Preclinical Data from TALGlobin01

Read more

28 Oct
2021
11:08 E.S.T.

Cellectis to Hold Third Quarter Earnings Call on Friday, November 5, 2021 at 8AM EDT

Read more

19 Oct
2021
14:19 E.S.T.

Cellectis Presents Initial Preclinical Data on Two Novel Gene Therapies for Patients with RAG1 Severe Combined Immunodeficiency (SCID) and Hyper IgE syndrome at ESGCT 2021

Read more

12 Oct
2021
14:53 E.S.T.

Cellectis to Present Preclinical Data on UCARTMESO Supporting Anti-Tumor Activity at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

Read more